共 258 条
[1]
Kris MG(2011)Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI’s Lung Cancer Mutation Consortium (LCMC) J Clin Oncol 29 CRA7506-1901
[2]
Johnson BE(2011)Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations J Thorac Oncol 6 1895-774
[3]
Kwiatkowski DJ(2010)Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer Nat Rev Cancer 10 760-2388
[4]
Iafrate AJ(2010)North-East Japan Study Group: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Eng J Med 362 2380-246
[5]
Wistuba II(2012)Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 239-vii64
[6]
Aronson SL(2012)ESMO Guidelines Working Group: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 vii56-10
[7]
Engelman JA(2011)Italian Association of Thoracic Oncology: Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines Lung Cancer 73 1-6096
[8]
Shyr Y(2011)Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Sci Transl Med 3 75ra26-198
[9]
Khuri FR(2008)Epidermal growth factor receptor mutations in small cell lung cancer Clin Cancer Res 14 6092-413
[10]
Rudin CM(2011)Epidermal growth factor receptor mutations in small cell lung cancer: a brief report J Thorac Oncol 6 195-215